[Federal Register Volume 72, Number 128 (Thursday, July 5, 2007)]
[Notices]
[Page 36728]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-12955]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on March 2, 2007, Amri 
Rensselaer, Inc., 33 Riverside Avenue, Rensselaer, New York 12144, made 
application by letter to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of Lisdexamfetamine (1205), a 
basic class of controlled substance listed in schedule II.
    The company plans to manufacture the listed controlled substance in 
bulk for sales to its customer.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Drug Enforcement 
Administration, Office of Diversion Control, Federal Register 
Representative (ODL), Washington, DC 20537, or any being sent via 
express mail should be sent to Drug Enforcement Administration, Office 
of Diversion Control, Federal Register Representative (ODL), 2401 
Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed 
no later than September 4, 2007.

    Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E7-12955 Filed 7-3-07; 8:45 am]
BILLING CODE 4410-09-P